Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VH5356136 Formulation 1
- Development stage
- Phase 1
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
**VH5356136 Formulation 1** is an investigational long-acting parenteral formulation of VH5356136, being developed by ViiV Healthcare for the treatment and prevention of HIV-1 infection. VH5356136 is a derivative or prodrug of the parent compound VH4524184 (VH-184), which is a third-generation integrase strand transfer inhibitor (INSTI) designed to have a high barrier to resistance and long-acting potential. VH5356136 Formulation 1 is being evaluated in a Phase 1 clinical trial (NCT07822477) to assess its safety, tolerability, and pharmacokinetics following a single parenteral dose in healthy adult participants without HIV.
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on VH5356136 Formulation 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VH5356136 Formulation 1.